

The St. Gallen Model of Cooperative Management of Ovarian Cancer Patients



R. Hornung, St. Gallen


Epidemiology

Ovarian cancer incidence:

Cancer Registry St. Gallen –
Appenzell (2010-2012):

- 46 Ovarian cancers/ year
- ~2/3 stage III+IV (~ 30 pats)

Die häufigsten krebsbedingten Neuerkrankungen bei Frauen



St.Gallen-Appenzell 2010-2012

Diagnostics

Referring Gynecologist


1. Gynecologic examination
 2. Transvaginal + transabdominal sonography
 3. Suspicion for ovarian cancer → Admission to a tertiary hospital specialized for gynecologic oncology
- }
- *

Gynecologic Cancer Center


1. General checkup
2. Laboratory: Routine hematology and blood chemistry, Ca 125, CEA (in special cases HCG, AFP and other markers)
3. CAT-scan abdomen (chest)
4. Colonoscopy (the day before surgery)

*S3 Guidelines 2013


Patient's path, decision making




Decision making



Decision making



Prognosis




The higher the FIGO stage, the poorer the prognosis

Prognosis

Cancer 2009;115:1234-44.


Residual tumor following surgery



Prognosis

J Gynecol Oncol Vol. 19, No. 4:223-228, 2008


Residual tumor following surgery



Prognosis

Residual tumor following surgery

International Journal of Surgical Oncology
Volume 2010, Article ID 214919, 8 pages




Therapy




Cytoreduction

Residual disease > 1cm versus microscopic disease



Primary surgery is of utmost importance for the patient's survival



Therapy

Surgery of ovarian cancer

Hysterectomy

Bilateral salpingo-oophorectomy

Omentectomy

Pelvine and paraaortal lymphadenectomy


Appendectomy (mucinous ovarian cancer)

Bowel resection (rectum, colon, small intestine) with anastomosis


Splenectomy

Peritonectomy


Therapy



Therapy




Preferential sites for
metastasis




Systematic inspection of
the abdominal cavity


Therapy




Therapy




Therapy



Therapy




Therapy




Therapy

J Clin Oncol 28:1733-1739. © 2010.



Lymphadenectomy R0

Lymphadenectomy R1



Lymphadenectomy R0 and no
macroscopic suspicious LN


Therapy

*Journal of Ovarian
Research* 2014,
Giorda et al. .

| | | | |
|--------------------------------------------------------|---------|-------|---|
| Bowel Resection | 116/301 | 38.5% | |
| Rectosigmoidectomy Only | 81/116 | 69,8% | ← |
| Upper Bowel Surgery Only | 17/116 | 14,7% | |
| Rectosigmoidectomy and Upper Bowel Surgery | 18/116 | 15,5% | |
| Pelvic Peritonectomy Only | 133/301 | 44,2% | |
| Upper Abdominal Procedures Only | 13/301 | 4,3% | |
| Pelvic Peritonectomy and Upper Abdominal Procedures | 69/301 | 22,9% | |
| Upper Abdominal Procedures | 82/301 | 27.2% | ← |
| Diaphragmatic Peritoneum Stripping | 45/82 | 54,9% | ← |
| Splenectomy | 31/82 | 37,8% | |
| Colecystectomy | 16/82 | 19,5% | |
| Liver Metastasectomy | 5/82 | 6,1% | |
| Partial Gastrectomy | 3/82 | 3,6% | |
| Distal Pancreatectomy | 3/82 | 3,6% | |
| Diaphragmatic Full-Thickness Resection | 2/82 | 2,4% | |
| Hepatic Hilum Lymphadenectomy | 1/82 | 1,4% | |
| Celiac Lymphadenectomy | 1/82 | 1,4% | |
| Retroperitoneal Lymphadenectomy | 196/301 | 65.1% | ← |
| Pelvic Lymphadenectomy | 188/196 | 95.9% | |
| Aortic Lymphadenectomy | 149/196 | 74.5% | |

Therapy

Hazzard ratio for dying due to ovarian cancer



Gynecologic Oncology 112 (2009) 422-436

Gyn-oncologist

Ob / Gyn

Therapy

Ovarian cancer incidence:


Cancer Registry St. Gallen –
Appenzell (2010-2012):

- 46 Ovarian cancers / year
- ~2/3 stage III+IV (~ 30 pats)

About 20 surgeries for stage III/IV
ovarian cancer / y requested for
adequate quality of care



→ In east of Switzerland only 1
center possible / reasonable

Die häufigsten krebsbedingten Neuerkrankungen bei Frauen



St.Gallen-Appenzell 2010-2012

Additive Chemotherapy




6 cycles of Carboplatin 5AUC + 175 mg/m² Paclitaxel every 3 weeks (Paclitaxel weekly)

Some indications: + Bevacizumab



Therapy

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer



Therapy

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy

Gynecologic Oncology 131 (2013) 437–444

Survival and **quality of life** of patients with ovarian cancer
III / IV

neoadjuvant chemotherapy + secondary debulking

=

primary surgery + adjuvant chemotherapy

→ Survival and quality of life are significantly better when the patient is treated in a gyn-onc center

Therapy

Patients profiting from **primary debulking surgery**

- Stage IIIA/B
- Stage IIIC radical operable (R0 very likely to be achieved)

Patients profiting from neoadjuvant chemotherapy followed by interval debulking

- Stage IIIC R0 very likely not to be achieved (small bowel)
- Stage IV (probability for R0 resection < 10%)
- Poor general condition
- Logistic problems

→ **Individual decision (team, experience)**

